Tisotumab vedotin potential to fill unmet needs in oncology market, says analyst

Following a study published in The Lancet Oncology regarding a brand new type of cancer drug that has shown promise in multiple cancer types in early Phase I/II trials, Philippa Salter, pharma analyst at data and analytics firm GlobalData, offers her views, nothing that “although cancer treatment has significantly advanced over the past few decades, there are still many ‘difficult-to-treat’ cancers, particularly when they reach more advanced stages.”

However, she says, this trial showed that tisotumab vedotin caused a response in a significant minority of patients with advanced stage cancer who had already failed to respond to at least three treatments on average, which shows the promise that this therapy can fill unmet needs in the oncology market, providing further treatment options for patients who have currently run out of options.

Tisotumab vedotin is being developed by biotech companies Genmab (OMX: GEN) and Seattle Genetics (Nasdaq: SGEN), in partnership with the UK’s Institute of Cancer Research, London, which conducted the trial reported in The Lancer Oncology.